[go: up one dir, main page]

WO2012090179A2 - Dérivés d'isoquinoline en tant que modulateurs des récepteurs cannabinoïdes - Google Patents

Dérivés d'isoquinoline en tant que modulateurs des récepteurs cannabinoïdes Download PDF

Info

Publication number
WO2012090179A2
WO2012090179A2 PCT/IB2011/056012 IB2011056012W WO2012090179A2 WO 2012090179 A2 WO2012090179 A2 WO 2012090179A2 IB 2011056012 W IB2011056012 W IB 2011056012W WO 2012090179 A2 WO2012090179 A2 WO 2012090179A2
Authority
WO
WIPO (PCT)
Prior art keywords
pain
isoquinolin
amino
methanone
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/056012
Other languages
English (en)
Other versions
WO2012090179A3 (fr
Inventor
Sanjeev Anant Kulkarni
Sachin MADAN
Nirmal Kumar JANA
Sachin Jaysing Mahangare
Prashant Vitthalrao TALE
Seema Prabhakar ZADE
Amolsing Dattu PATIL
Narasimha Murthy CHEEMALA
Venkata P. Palle
Rajender Kumar Kamboj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of WO2012090179A2 publication Critical patent/WO2012090179A2/fr
Publication of WO2012090179A3 publication Critical patent/WO2012090179A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Definitions

  • the present invention relates to compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions for the treatment, prevention, management, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors.
  • the invention also relates to methods of treating, preventing, managing and/or lessening the severity of the diseases disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors.
  • the invention also relates to processes for the preparation of the compounds of the invention.
  • CX5 G-protein coupled receptor expressed in human promyelocytic leukemic cell line (HL60) was discovered in 1993. This was later identified as type II Cannabinoid receptor (Munro et al. Nature (1993), 365, 61 -65). CB 2 receptors are found to be expressed predominantly in immune cells. When activated they modulate immune cell migration and cytokine release outside and within the brain (Pertwee et al. Handb. Exp. Pharmacol. (2005), 168, 1-51 ). CB 2 activation affects a host of immune responses from inflammation to neuroprotection (Cabral et al. Handb. Exp. Pharmacol. (2005), 168, 385 ⁇ 123). The activation of CB 2 receptors is reported to have analgesic effect in many animal models of pain from acute pain to neuropathic pain (Anand et al. Pain. (2009), 138, 667-680).
  • CB 2 is an attractive therapeutic target for pain management and immune system modulation without overt psycho activity and substance abuse possibility, its presumed absence in the CNS was reviewed by many researchers. The findings of these recent investigations support the presence of CB 2 receptors in CNS.
  • the CB 2 mRNA and protein have been found in microglia (Beltramo et al. Eur. J. Neurosci. (2006), 23, 1530-1538; Carlisle et al. Int. Immuno Pharmacol. (2002), 2, 69-82; Klegeris et al. Br. J. Pharmacol. (2003), 139, 775-786; Maresz et al., Nat. Med. (2007), 13, 492-497; Walter et al. J. Neurosci.
  • CB 2 The expression levels of CB 2 are proportional to the activation extent of microglia (Cabral et al., Br. J. Pharmacol. (2008), 153, 240-251 ; Pietr et al. FEBS Lett. (2009), 583, 2071 -2076; Stella et al. Glia. (2004), 48, 267-277). Microglial migration and their infiltration into brain areas with active neuroinflammation and degeneration are modulated by CB 2 . In healthy brain microglia does not express CB 2 but they do in Alzheimer's brain tissue in the neuritic-plaque associated microglia (Benito et al. J Neurosci.
  • CB 2 mRNA is found to increase in association with activated microglia in the spinal cord (Zhang et al. Eur. J. Neurosci. (2003), 17, 2750-2754). Similarly in amyotrophic lateral sclerosis and multiple sclerosis, CB 2 microglial expression increases in spinal cord (Yiangou et al. BMC. Neurol. (2006), 6, 12).
  • CB 2 receptor distribution is also known in macrophages, CD4 T cells, CD8 T cells, B cells, natural killer cells, monocytes, and polymorphonuclear neutrophils (Dittel B N. et al. BJP. (2008), 153, (2), 271 -276; Maresz K. et al. Nature Medicine. (2007), 13, 492-497).
  • CB 2 receptor presence is also known in other brain areas like thalamus, straitum, hippocampus.
  • Peripheral neurons, nociceptive neurons and sensory neurons also are known to express CB 2 receptors.
  • CB 2 receptor is expressed in the bone cells and is reported to have anabolic effect on bones (Ofek et al. PNAS. (2006), 103, 696-701 ). Presence of CB 2 is also reported in the enteric nervous system, (Duncan M Mouihate et al, Am. J. Physiol. Gastrointest. Liver Physiol. 295, G78-G87). Similar anabolic effect is also reported through CB2 receptor mediation in neurogenesis (Molina-Holgado et al. Eur. J. Neurosci. (2007), 25, 629-634 & Palazuelos J. et al FASEB J. (2006), 20, 2405-2407).
  • CB1 in pain management is also well known. This receptor is known to exist majorly in the central nervous system. To a minor extent, CB1 is also reported to exist in the periphery (Pharmacology, Biochemistry and Behavior 90 (2008) 501-51 1 ). Therefore, along with compounds that are CB2 selective modulators, dual modulators working through CB1 and CB2 are also targeted.
  • WO 2002/042248, WO 2010/096371 , WO 2010/133973, WO 2006/129178, WO 2010/ 084767, WO 2009/053799, WO 2008/1 15672, WO 2008/027812, WO 2007/102059, WO 2007/091950 and WO 2002/42248 applications disclose compounds related to cannabinoid receptors for the treatment of various diseases mediated by cannabinoid receptors. Also, Bioorganic Medicinal Chemistry, (201 1 ), 19, 939-950, discloses the compounds related to cannabinoid receptors.
  • the invention provides compounds having the Formula (I):
  • X is selected from -NR a -, -O- and -S(O) n -;
  • Y is selected from -C(O)-, -S(O) 2 -, and -CR 5 R 6 -;
  • R 1 which may be same or different at each occurrence, is independently selected from halogen, cyano, nitro, hydroxy, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, alkoxy, cycloalkoxy, -C(O)OH, -NR a R b and -C(O)NR a R b ;
  • R 2 is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyi, heteroaryl, heteroarylalkyi, heterocyclyl, and heterocyclylalkyi;
  • R 3 is selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyi, heteroaryl, heteroarylalkyi, heterocyclyl, and heterocyclylalkyi; or
  • R 2 and R 3 together with the nitrogen atom to which they are attached, may form a substituted or an unsubstituted 3 to 14 membered heterocyclic ring;
  • R 2 and R 3 together with the nitrogen atom to which they are attached, may form a substituted or an unsubstituted 5 to 14 membered heteroaryl ring;
  • R 4 is selected from cycloalkyl, aryl, heteroaryl and heterocyclyl
  • R 5 and R 6 which may be same or different, are independently selected from hydrogen, alkyl, and haloalkyl;
  • R a and R b which may be same or different at each occurrence, are independently selected from hydrogen, alkyl, haloalkyl, acyl and cycloalkyl; or R a and R b, together with the nitrogen atom to which they are attached, may form a substituted or unsubstituted 3 to 14 membered heteroaryl or heterocyclic ring;
  • 'm' is an integer ranging from 0 to 3, both inclusive;
  • 'n' is an integer ranging from 0 to 2, both inclusive;
  • R 7 which may be same or different at each occurrence, is independently selected from halogen, cyano, nitro, hydroxy, alkyl, haloalkyi, hydroxyalkyl, cycloalkyi, alkoxy, haloalkoxy, cycloalkoxy, -C(0)OH, -NR a R b and -C(0)NR a R b ;
  • R 2 , R3, R a , and R b are as defined herein above;
  • 'p' is an integer ranging from 0 to 4, both inclusive;
  • R 7 which may be same or different at each occurrence, is independently selected from halogen, cyano, nitro, hydroxy, alkyl, haloalkyi, hydroxyalkyl, cycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, -C(0)OH, -NR a R b and -C(0)NR a R b ;
  • W is CR 8 R 9 , O, or S(0) 2 ;
  • R 8 and R 9 are independently selected from hydrogen, halogen, cyano, hydroxy, alkyl, haloalkyi, hydroxyalkyl, cycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, heteroaryl, heterocyclyl, -NR a Rb and -C(0)NR a Rb;
  • R 7 is not p-methyl or o-methoxy
  • R 7 is not p-methyl, o- methoxy, p-methoxy or p-halogen
  • R a and R b are as defined herein above;
  • 'p' is an integer ranging from 0 to 4, both inclusive;
  • R 3 is selected from alkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl.
  • substituent(s) on heterocyclic ring may be one or more, same or different and are independently selected from halogen, alkyl, haloalkyl, aryl or heteroaryl.
  • a compound of formula (I) useful in treating, preventing, managing and/or lessening the severity of diseases, disorders, syndromes or conditions associated with cannabinoid (CB) modulators.
  • the invention provides a pharmaceutical composition that includes at least one compound of formula (I) and at least one pharmaceutically acceptable excipient.
  • the invention provides a pharmaceutical composition of compound of formula (I) useful in treating, preventing, managing and/or lessening the severity of the diseases disorders or conditions associated with cannabinoid (CB) modulators in a subject, in need thereof by administering to the subject, one or more compounds described herein in a therapeutically effective amount to cause modulation of such receptor. Also provided herein are processes for preparing compounds described herein.
  • halogen or halo means fluorine, chlorine, bromine, or iodine.
  • alkyl refers to an alkane derived hydrocarbon radical that includes solely carbon and hydrogen atoms in the backbone, contains no unsaturation, has from one to six carbon atoms, and is attached to the remainder of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1 -methylethyl (isopropyl), n-butyl, n-pentyl, 1 ,1 - dimethylethyl (t-butyl) and the like. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkenyl refers to a hydrocarbon radical containing from 2 to 10 carbon atoms and including at least one carbon-carbon double bond.
  • alkenyl groups include ethenyl, 1 -propenyl, 2-propenyl (allyl), iso- propenyl, 2-methyl-l- propenyl, 1 -butenyl, 2-butenyl and the like. Unless set forth or recited to the contrary, all alkenyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkynyl refers to a hydrocarbon radical containing 2 to 10 carbon atoms and including at least one carbon- carbon triple bond.
  • Non- limiting examples of alkynyl groups include ethynyl, propynyl, butynyl and the like. Unless set forth or recited to the contrary, all alkynyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkoxy refers to an alkyl group attached via an oxygen linkage. Non- limiting examples of such groups are methoxy, ethoxy and propoxy and the like. Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkenyloxy refers to an alkenyl group attached via an oxygen linkage.
  • Non-limiting examples of such groups are vinyloxy, allyloxy, 1 -butenyloxy, 2- butenyloxy, isobutenyloxy, 1 -pentenyloxy, 2-pentenyloxy, 3-methyl-1 -butenyloxy, 1 - methyl-2-butenyloxy, 2,3-dimethylbutenyloxy, 1 -hexenyloxy and the like.
  • all alkenyloxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkynyloxy refers to an alkynyl group attached via an oxygen linkage.
  • Non-limiting examples of such groups are acetylenyloxy, propynyloxy, 1 -butynyloxy, 2-butynyloxy, 1 -pentynyloxy, 2-pentynyloxy, 3-methyl-1 -butynyloxy, 1 -hexynyloxy, 2- hexynyloxy, and the like.
  • cycloalkyl refers to a non-aromatic mono or multicyclic ring system having 3 to 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or spirobicyclic groups, e.g., spiro(4,4)non-2-yl and the like. Unless set forth or recited to the contrary, all cycloalkyi groups described or claimed herein may be substituted or unsubstituted.
  • cycloalkoxy refers to an cycloalkyi, defined herein, group attached via an oxygen linkage.
  • Non-limiting examples of such groups are cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexyloxy and the like. Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • cycloalkenyl refers to a non-aromatic mono or multicyclic ring system having 3 to 12 carbon atoms and including at least one carbon-carbon double bond, such as cyclopentenyl, cyclohexenyl, cycloheptenyl and the like. Unless set forth or recited to the contrary, all cycloalkenyl groups described or claimed herein may be substituted or unsubstituted.
  • cycloalkylalkyl refers to a cycloalkyi group as defined above, directly bonded to an alkyl group as defined above, e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, etc. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • haloalkyi refers to an alkyl group as defined above that is substituted by one or more halogen atoms as defined above.
  • the haloalkyi may be monohaloalkyl, dihaloalkyl or polyhaloalkyl including perhaloalkyl.
  • a monohaloalkyl can have one iodine, bromine, chlorine or fluorine atom.
  • Dihaloalkyl and polyhaloalkyl groups can be substituted with two or more of the same halogen atoms or a combination of different halogen atoms.
  • a polyhaloalkyl is substituted with up to 12 halogen atoms.
  • Non-limiting examples of a haloalkyi include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl and the like.
  • a perhaloalkyl refers to an alkyl having all hydrogen atoms replaced with halogen atoms.
  • haloalkoxy refers to an haloalkyl, defined herein, group attached via an oxygen linkage.
  • Non-limiting examples of such groups are monohaloalkoxy, dihaloalkoxy or polyhaloalkoxy including perhaloalkoxy.
  • all haloalkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • hydroxyalkyl refers to an alkyl group, as defined above that is substituted by one or more hydroxy groups.
  • the hydroxyalkyl is monohydroxyalkyl or di hydroxyalkyl.
  • Non-limiting examples of a hydroxyalkyl include 2- hydroxyethyl, 3- hydroxypropyl, 2-hydroxypropyl, and the like.
  • aryl refers to an aromatic radical having 6- to 14- carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems, such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl and the like. Unless set forth or recited to the contrary, all aryl groups described or claimed herein may be substituted or unsubstituted.
  • arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH 2 C 6 H 5 and -C 2 H 4 C 6 H 5 . Unless set forth or recited to the contrary, all arylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • heterocyclic ring or “heterocyclyl ring” or “heterocyclyl”, unless otherwise specified, refers to substituted or unsubstituted non-aromatic 3- to 15- membered ring which consists of carbon atoms and with one or more heteroatom(s) independently selected from N, O or S.
  • the heterocyclic ring may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems and the nitrogen, carbon, oxygen or sulfur atoms in the heterocyclic ring may be optionally oxidized to various oxidation states.
  • heterocyclic ring may also be fused with aromatic ring.
  • heterocyclic rings include azepinyl, azetidinyl, benzodioxolyl, benzodioxanyl, benzopyranyl, chromanyl, dioxolanyl, dioxaphospholanyl, decahydroisoquinolyl, indanyl, indolinyl, isoindolinyl, isochromanyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, octahydroindolyl, octahydroisoindolyl, perhydroazepinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, piperidiny
  • heterocyclic ring may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted; substituents may be on same or different ring atom.
  • heteroaryl refers to a substituted or unsubstituted 5- to 14- membered aromatic heterocyclic ring with one or more heteroatom(s) independently selected from N, O or S.
  • the heteroaryl may be a mono-, bi- or tricyclic ring system.
  • the heteroaryl ring may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
  • Non-limiting examples of a heteroaryl ring include oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazolyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolyl, isoquinolyl, thiadiazolyl, indolizinyl, acridinyl
  • heterocyclylalkyl refers to a heterocyclic ring radical directly bonded to an alkyl group.
  • the heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • heteroarylalkyi refers to a heteroaryl ring radical directly bonded to an alkyl group.
  • the heteroarylalkyi radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heteroarylalkyi groups described or claimed herein may be substituted or unsubstituted.
  • substituted refers to a group or moiety having one or more substituents attached to the structural skeleton of the group or moiety.
  • the phrase "may optionally be substituted” refers to a moiety or group that may or may not be substituted.
  • optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted and unsubstituted aryl radicals.
  • a "stereoisomer” refers to a compound having the same atoms bonded through the same bonds but having different three-dimensional orientations, which are not interchangeable.
  • the invention contemplates various stereoisomers and mixtures thereof and includes enantiomers and diastereomers.
  • the invention also includes geometric isomers ⁇ " or "Z” or cis or trans configuration in a compound having either a double bond or having substituted cycloalkyl ring system.
  • a “tautomer” refers to a compound that undergoes rapid proton shifts from one atom of the compound to another atom of the compound. Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. The individual tautomers as well as mixture thereof are encompassed with compounds of formula (I).
  • treating or “treatment” of a state, disease, disorder, condition or syndrome includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disease, disorder, condition or syndrome developing in a subject that may be afflicted with or predisposed to the state, disease, disorder, condition or syndrome but does not yet experience or display clinical or subclinical symptoms of the state, disease, disorder, condition or syndrome; (b) inhibiting the state, disease, disorder, condition or syndrome, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; c) lessening the severity of a disease, disorder, syndrome or condition or at least one of its clinical or subclinical symptoms thereof; and/or (d) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • modulate refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule. By way of illustration and not limitation, it includes agonists, partial agonists, inverse agonists and antagonists of a cannabinoid (CB) receptor of the present invention.
  • CB cannabinoid
  • subject includes mammals, preferably humans and other animals, such as domestic animals; e.g., household pets including cats and dogs.
  • a “therapeutically effective amount” refers to the amount of a compound that, when administered to a subject in need thereof, is sufficient to cause a desired effect.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity, age, weight, physical condition and responsiveness of the subject to be treated.
  • the compounds of the invention may form salts.
  • administration of the compound as a pharmaceutically acceptable salt may be appropriate.
  • pharmaceutically acceptable salts are organic acid addition salts formed by addition of acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, a-glycerophosphate, formate, fumarate, propionate, glycolate, lactate, pyruvate, oxalate, maleate, and salicylate.
  • Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate, carbonate salts, hydrobromate and phosphoric acid.
  • salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • the invention extends to stereoisomeric forms and to mixtures thereof.
  • the different stereoisomeric forms of the invention may be separated from one another by the method known in the art, or a given isomer may be obtained by stereospecific or asymmetric synthesis.
  • Tautomeric forms and mixtures of compounds described herein are also contemplated. Screening of compounds of invention for cannabinoid receptor modulation activity can be achieved by using various in vitro and in vivo protocols mentioned herein below or methods known in the art.
  • the invention relates to pharmaceutical composition containing the compounds of the Formula (I) disclosed herein.
  • pharmaceutical compositions containing a therapeutically effective amount of at least one compound of formula (I) described herein and at least one pharmaceutically acceptable excipient (such as a carrier or diluent).
  • the contemplated pharmaceutical compositions include the compound(s) described herein in an amount sufficient to modulate cannabinoid receptor mediated diseases described herein when administered to a subject.
  • the subjects contemplated include, for example, a living cell and a mammal, including human mammal.
  • the compound of the invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient includes a pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
  • suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicylic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing osmotic pressure, buffers, sweetening agents, flavoring agents, colorants, or any combination of the foregoing.
  • the pharmaceutical composition of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
  • the pharmaceutical compositions described herein may be prepared by conventional techniques known in the art.
  • the active compound can be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper, or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container, for example, in a sachet.
  • the pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or products for topical application.
  • the route of administration may be any route which effectively transports the active compound of the invention to the appropriate or desired site of action.
  • Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment).
  • Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions. For parenteral application, particularly suitable are injectable solutions or suspensions formulation.
  • Liquid formulations include, but are not limited to, syrups, emulsions, suspensions, solutions, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as pocketed tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the total daily dose of the compounds of the invention depends, of course, on the mode of administration.
  • oral administration may require a higher total daily dose, than an intravenous (direct into blood).
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg according to the potency of the active component or mode of administration.
  • Suitable doses of the compounds for use in treating the diseases and disorders described herein can be determined by those skilled in the relevant art.
  • Therapeutic doses are generally identified through a dose ranging study in subject based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects for the patient.
  • the daily dosage of the CB modulator can range from about 0.1 to about 30.0 mg/kg.
  • Mode of administration, dosage forms, suitable pharmaceutical excipients, diluents or carriers can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the invention.
  • the invention provides compounds and pharmaceutical compositions thereof that are useful in treating, preventing, managing and/or lessening the severity of diseases, disorders, syndromes or conditions modulated by cannabinoid receptor.
  • the invention further provides method of treating diseases, disorders or conditions modulated by cannabinoid receptor in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound or a pharmaceutical composition of the invention.
  • the methods provided are also useful for diagnosis of conditions that can be treated by acting on cannabinoid receptor for determining if a patient will be responsible to therapeutic agents.
  • the invention provides a method for the treatment of diseases, disorders or conditions through modulating cannabinoid receptor. In this method, a subject in need of such treatment is administered a therapeutically effective amount of a compound of formula (I) described herein.
  • the compound of formula (I), being modulators of cannabinoid receptor, is potentially useful in treating, preventing, managing and/or lessening the severity of diseases, disorders, syndromes or conditions include but are not limited to pain, inflammation, analgesic conditions, healing of wounds and burns, movement disorders, immune disorders (such as autoimmune disorders), respiratory disorders, lung diseases associated with inflammation, pruritis associated with inflammation, allergic diseases associated with inflammation, organ contraction, preanesthetic medication, pre operative medication, muscle spasm, locomotor activity disorders, bone disorders, multiple sclerosis, glaucoma and related intra ocular pressure, cell growth disorders, gastrointestinal disorders, diseases of central nervous system (CNS) erythromyalgia, neurological disorders, neurodegenerative disorders, neuromuscular conditions, neuroinflammatory pathologies and the like.
  • CNS central nervous system
  • Pain includes, but is not limited to, acute pain, chronic pain, musculoskeletal pain, post-operative pain, visceral pain, peripherally mediated pain, centrally mediated pain, inflammatory pain, neuropathic pain, nociceptive pain, and idiopathic pain.
  • the compounds, compositions and methods of the invention are of particular use in treating, preventing or lessening of pain includes but is not limited to acute pain, chronic pain, visceral pain, neuropathic pain, inflammatory pain or nociceptive pain or pain associated with, such as but are not limited to dental pain, eye pain, ear pain, perioperative, traumatic pain, muscle pain, pain in burned skin, sun burn, trigeminal neuralgia, spasm of the gastrointestinal tract or uterus, colics, back pain, chronic fatigue syndrome, clinical depression, complex regional pain syndrome, myofascial pain syndrome, post-vasectomy pain syndrome, restless leg syndrome, spinal stenosis, chronic pelvic pain, pancreatitis, peptic ulcer, interstitial cystitis, renal colic, angina, dysmenorrhoea, menstruation, gynaecological pain, irritable bowel syndrome (IBS), non-ulcer dyspepsia, non-cardiac chest pain, myocardial isch
  • the compounds of the invention may be useful for treating various types of inflammatory disease such as inflammations due to immune system, inflammations due to cancer, atherosclerosis, ischaemic heart diseases, pancreatitis, which includes but is not limited to acute pancreatitis and chronic pancreatitis, which is characterized by recurring or persistent abdominal pain with or without steatorrhea hereditary pancreatitis, pancreatic dysfunction.
  • inflammatory disease such as inflammations due to immune system, inflammations due to cancer, atherosclerosis, ischaemic heart diseases, pancreatitis, which includes but is not limited to acute pancreatitis and chronic pancreatitis, which is characterized by recurring or persistent abdominal pain with or without steatorrhea hereditary pancreatitis, pancreatic dysfunction.
  • Respiratory related syndromes, disorders or diseases include, but are not limited to, diseases of the respiratory tract or lung diseases such as asthma, bronchitis (acute or chronic), emphysema, allergic rhinitis, emphysema, adult respiratory distress syndrome (ARDS), pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease (COPD), asthma including allergic asthma (atopic or non-atopic) as well as exercise-induced bronchoconstriction, occupational asthma, viral- or bacterial exacerbation of asthma, other non-allergic asthmas and "whez- infant syndrome", pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • diseases of the respiratory tract or lung diseases such as asthma, bronchitis (acute or chronic), emphyse
  • the compounds of invention may be useful in the treatment of pruritus and related diseases including, but not limited to psoriatic pruritis, itch due to hemodyalisis, aguagenic pruritis, itching caused by skin disorders, allergic itch, insect bite itch, itch caused by hypersensitivity such as dry skin, acne, eczema, psoriasis or injury, itch caused by vulvar vestibulitis and the similar itch.
  • pruritus and related diseases including, but not limited to psoriatic pruritis, itch due to hemodyalisis, aguagenic pruritis, itching caused by skin disorders, allergic itch, insect bite itch, itch caused by hypersensitivity such as dry skin, acne, eczema, psoriasis or injury, itch caused by vulvar vestibulitis and the similar itch.
  • Allergic diseases all forms of allergic reactions include but are not limited to angioneurotic edema, hay fever, insect bites, viral or bacterial diseases, allergic reactions to drugs, blood derivatives, contrast agents, delayed or immediate hypersensitivity, allergic rhinitis, contact dermatitis, conjunctivitis, allergic reactions associated with inflammatory diseases such as diseases of the joints, spondylitis, gout, vasculitis, Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or osteoporosis.
  • inflammatory diseases such as diseases of the joints, spondylitis, gout, vasculitis, Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or osteoporosis.
  • Autoimmune or inflammation related syndromes, disorders or diseases include, but are not limited to, psoriasis, lupus erythematosus, diseases of the connective tissue, Sjogren's syndrome, ankylosing spondylarthritis, rheumatoid arthritis, reactional arthritis, undifferentiated spondylarthritis, Behcet's disease, autoimmune hemolytic anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amyloses, graft rejection or diseases affecting the plasma cell line.
  • Gastrointestinal diseases including, but not limited to inflammatory bowel diseases, irritable bowel syndrome, regional enteritis (Crohns disease), colitis ulcerosa, gastritis, or aphthous.
  • the compounds described herein may be prepared by techniques known in the art.
  • the compounds described herein may be prepared by following the reaction sequence as depicted in Scheme-1 .
  • reaction sequence as depicted in Scheme-1 .
  • specific bases, acids, reagents, solvents, coupling agents, etc. are mentioned, it is understood that other bases, acids, reagents, solvents, coupling agents etc., known in the art may also be used and are therefore included within the scope of the present invention.
  • Variations in reaction conditions, for example, temperature and/or duration of the reaction which may be used as known in the art are also within the scope of the present invention. All the isomers of the compounds in described in these schemes, unless otherwise specified, are also encompassed within the scope of this invention.
  • the compound of formula (9) where X, R 1 ; R 2, R3, R 4 and 'm' are as described herein above, can be prepared by following the sequential transformations of isoquinoline as depicted in Scheme-1 .
  • the cyano compound of formula (2) undergoes hydrolysis in presence of KOH and the resultant acid compound (3) undergoes esterification to give compound of formula (4) in the presence of EDCI (1 -Ethyl-3-(3-dimethyl aminopropyl)carbodiimide), HOBt (hydroxybenzotriazole), DMAP (dimethyl aminopyridine) and in suitable solvent and this is further treated with mCPBA (m- chloroperbenzoic acid) to afford /V-oxide compound of formula (5).
  • This N-oxide compound of formula (5) is treated with POCI 3 to give chloro compound of formula (6) which is further reacted with compound R 4 -XH in the presence of Pd or Cu in suitable solvent to afford compound of formula (7).
  • Methyl 1 -chloroisoquinolin-4-carboxylate Methyl 2-oxideisoquinolin-4-carboxylate (lntermediate-5) (700 mg, 3.4 mmol) was dissolved in CHCI 3 (10 mL) and to this, POCI 3 (1 .1 mL, 12.1 mmol) was added at room temperature and the reaction mixture was refluxed for 1 h. It was then cooled to room temperature, concentrated, diluted with ice water, neutralized with K 2 C0 3 and extracted with EtOAc. The organic layer was separated, dried over Na 2 S0 4 , filtered and concentrated to give the crude product that was purified by flash column (10% EtOAC:Hexanes) to afford the title compound (380 mg, 50%) as a white solid.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) (1 equivalent) and 3-fluoroaniline (1 .5 equiv) by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 3,5-difluoroaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 2,4-difluoroaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 3,4-difluorophenol by following a procedure similar to that described in lntermediate-7e.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 2-methoxyaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 4-methoxyaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 3-chloro-4-methylaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 2,3-difluoroaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 3-(trifluoromethyl)aniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 3-chloro-2-fluoroaniline by following a procedure similar to that described in lntermediate-7a.
  • the title compound was prepared by using methyl 1 -chloroisoquinolin-4- carboxylate (lntermediate-6) and 2-fluoro-3-(trifluoromethyl)aniline by following a procedure similar to that described in lntermediate-7a.
  • Intermedite-8a 1 -((3-Chlorophenyl)amino)isoquinolin-4-carboxylic acid:
  • Intermedite-8c 1 -((3,5-Difluorophenyl)amino)isoquinolin-4-carboxylic acid:
  • lntermediate-8d 1 -((2,4-Difluorophenyl)amino)isoquinolin-4-carboxylic acid:
  • lntermediate-8h 1 -((4-Methoxyphenyl)amino)isoquinolin-4-carboxylic acid:
  • lntermediate-8i 1 -((3-Chloro-4-methylphenyl)amino)isoquinolin-4-carboxylic acid:
  • This compound was prepared by using lntermediate-81 and 1 ,1 -dioxidothio morpholine by following the similar procedure as described in Example-1 ;
  • Certain illustrative compounds within the scope of the invention are screened for CB 2 activity according to the procedure given below.
  • the screening of the compounds may also be carried by other methods and procedures known to skilled in the art.
  • In-vitro assay method for determination of cAMP in functional hCB?-CHO stable cells Recombinant CHO-hCB 2 cells (procured from Perkin Elmer Inc. USA) were propagated and maintained in Ham's F-12 complete medium containing 10% heat inactivated FBS (Sigma.UK) and 1 x penstrep. For assay, 0.1 x10 6 to 1 .0 x10 6 CHO- hCB 2 cells were seeded in T-25 flask and grown to mid-log phase in culture media without antibiotics for 2-3 days.
  • assay cell monolayer was washed twice with PBS (pH.7.4) and then cells were detached with PBS-EDTA, centrifuged and resuspended in assay buffer (KRBG containing: 1 15 mM NaCI, 5 mM KCI, 24 mM NaHCOs, 10 mM Glucose, 1 mM MgCI 2 , 2.5 mM CaCI 2 , 10 mM HEPES, 1 mM IBMX and 0.1 - 0.5 g/l BSA). The test is performed in 96 1 ⁇ 2 area black well plates.
  • cAMP calibrator/standards were added in the plate with range of 70 nM to 0.01 nM and 4-parameter curve fit (based on DF values) was used for calculation of cAMP concentration of sample wells.
  • vehicle control (0.4% v/v DMSO) was set to 0% and forskolin control wells as 100%.
  • the concentration of compound required to stimulate a half-maximal response (EC 5 o) was determined using the GraphPad Prism software (version 5).
  • the compounds prepared were tested using the above assay procedure and the results obtained are given below.
  • the EC 50 (nM) values of the compounds are set forth in Table-1 wherein "A” refers to an EC 50 value of less than 10 nM and "B” refers to an EC50 value in range of 10.01 to 1000 nM.
  • hCB1 -HEK cells (clone 8) were propagated and maintained in DMEM complete medium supplemented with 10% heat inactivated FBS (Sigma. U.S.A), 400 ⁇ 9/ ⁇ of G418 and 1 x penstrep.
  • FBS heat inactivated FBS
  • 0.6 - 1 .0 x10 6 hCB1 -HEK cells were seeded in T-25 flask and grown to mid-log phase in complete culture medium as mentioned above for 2-3 days.
  • cell monolayer was washed once with PBS (pH.7.4) and then serum starved for overnight in DMEM medium containing 0.2% bovine serum albumin (devoid of antibiotics, FBS and penstrep).
  • test On the day of assay, cells were trypsinized using 0.025% trypsin-EDTA, centrifuged and resuspended in assay buffer (KRBG containing: 1 15 mM NaCI, 5 mM KCI, 24 mM NaHCO3, 1 0 mM Glucose, 1 mM MgCI 2 , 2.5 mM CaCI2, 10 mM HEPES, 1 mM IBMX and 0.1 - 0.5 g/l BSA) at a concentration of 2.5 x 10 5 cells/ml. The test is performed in 96 1 ⁇ 2 area black well plates.
  • assay buffer KRBG containing: 1 15 mM NaCI, 5 mM KCI, 24 mM NaHCO3, 1 0 mM Glucose, 1 mM MgCI 2 , 2.5 mM CaCI2, 10 mM HEPES, 1 mM IBMX and 0.1 - 0.5 g/l BSA
  • cAMP calibrator/standards were added in the plate with range of 70 nM to 0.01 nM and 4-parameter curve fit (based on DF values) was used for calculation of cAMP concentration of sample wells.
  • vehicle control (0.4% v/v DMSO) was set to 0% and forskolin control wells were set as 100%.
  • Assay was validated using CP55940, WIN-55212-2 and SR144528 as reference compounds.
  • the compounds of the invention have EC 50 values in the nano molar (nM) to micro molar range ( ⁇ ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de Formule (I) ainsi que des procédés pour leur préparation, qui sont utiles pour le traitement, la prévention et/ou la gestion de maladies, troubles, syndromes ou états associés à la modulation des récepteurs cannabinoïdes (CB). L'invention concerne également des méthodes de traitement, de prévention, de gestion et/ou de diminution de maladies, troubles, syndromes ou états associés à la modulation des récepteurs cannabinoïdes (CB) de Formule (I).
PCT/IB2011/056012 2010-12-30 2011-12-29 Dérivés d'isoquinoline en tant que modulateurs des récepteurs cannabinoïdes Ceased WO2012090179A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1477/KOL/2010 2010-12-30
IN1477KO2010 2010-12-30
IN909KO2011 2011-07-05
IN909/KOL/2011 2011-07-05

Publications (2)

Publication Number Publication Date
WO2012090179A2 true WO2012090179A2 (fr) 2012-07-05
WO2012090179A3 WO2012090179A3 (fr) 2012-10-04

Family

ID=45529153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/056012 Ceased WO2012090179A2 (fr) 2010-12-30 2011-12-29 Dérivés d'isoquinoline en tant que modulateurs des récepteurs cannabinoïdes

Country Status (1)

Country Link
WO (1) WO2012090179A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013005168A3 (fr) * 2011-07-05 2013-04-25 Lupin Limited Modulateurs des récepteurs de cannabinoïdes
WO2017062500A3 (fr) * 2015-10-05 2017-05-26 The Trustees Of Columbia University In The City Of New York Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
CN112384503A (zh) * 2018-07-02 2021-02-19 洛桑联邦理工学院(Epfl) 乳酸增强化合物及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042248A2 (fr) 2000-11-24 2002-05-30 Novartis Ag Derives de naphtalene
WO2006129178A1 (fr) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation
WO2007091950A1 (fr) 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles et imidazopyridines utiles dans le traitement de maladies ou de troubles associés au récepteur cannabinoïde 2 (cb2) tels que la douleur
WO2007102059A1 (fr) 2006-03-06 2007-09-13 Pfizer Japan Inc. Derives de sulfonyl benzimidazole
WO2008027812A2 (fr) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Dérivés d'imidazopyridine et d'imidazopyrimidine
WO2008115672A1 (fr) 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Procédé de traitement d'une douleur induite par un récepteur cb2
WO2009053799A1 (fr) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Nouveaux ligands du récepteur cannobinoïde, compositions pharmaceutiques les contenant et leur procédé de préparation
WO2010084767A1 (fr) 2009-01-22 2010-07-29 Raqualia Pharma Inc. Composés de sulfone hétérocycliques saturés n-substitués ayant une activité agoniste du récepteur cb2
WO2010096371A2 (fr) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Composés hétérocycliques qui modulent le récepteur cb2
WO2010133973A1 (fr) 2009-05-20 2010-11-25 Universite Lille 2 Droit Et Sante Dérivés de la 1,4-dihydropyridine et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
CA2709784A1 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042248A2 (fr) 2000-11-24 2002-05-30 Novartis Ag Derives de naphtalene
WO2006129178A1 (fr) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation
WO2007091950A1 (fr) 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles et imidazopyridines utiles dans le traitement de maladies ou de troubles associés au récepteur cannabinoïde 2 (cb2) tels que la douleur
WO2007102059A1 (fr) 2006-03-06 2007-09-13 Pfizer Japan Inc. Derives de sulfonyl benzimidazole
WO2008027812A2 (fr) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Dérivés d'imidazopyridine et d'imidazopyrimidine
WO2008115672A1 (fr) 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Procédé de traitement d'une douleur induite par un récepteur cb2
WO2009053799A1 (fr) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Nouveaux ligands du récepteur cannobinoïde, compositions pharmaceutiques les contenant et leur procédé de préparation
WO2010084767A1 (fr) 2009-01-22 2010-07-29 Raqualia Pharma Inc. Composés de sulfone hétérocycliques saturés n-substitués ayant une activité agoniste du récepteur cb2
WO2010096371A2 (fr) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Composés hétérocycliques qui modulent le récepteur cb2
WO2010133973A1 (fr) 2009-05-20 2010-11-25 Universite Lille 2 Droit Et Sante Dérivés de la 1,4-dihydropyridine et leurs utilisations

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ANAND ET AL., PAIN, vol. 138, 2009, pages 667 - 680
BELTRAMO ET AL., EUR. J. NEUROSCI., vol. 23, 2006, pages 1530 - 1538
BENITO ET AL., J NEUROSCI., vol. 23, 2003, pages 11136 - 11141
BIOORGANIC MEDICINAL CHEMISTRY, vol. 19, 2011, pages 939 - 950
CABRAL ET AL., BR. J. PHARMACOL., vol. 153, 2008, pages 240 - 251
CABRAL ET AL.: "Handb. Exp. Pharmacol.", vol. 168, 2005, pages: 385 - 423
CARLISLE ET AL., INT. IMMUNO PHARMACOL., vol. 2, 2002, pages 69 - 82
DITTEL B N. ET AL., BJP., vol. 153, no. 2, 2008, pages 271 - 276
DUNCAN M MOUIHATE ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 295, pages G78 - G87
KLEGERIS ET AL., BR. J. PHARMACOL., vol. 139, 2003, pages 775 - 786
MARESZ ET AL., NAT. MED., vol. 13, 2007, pages 492 - 497
MARESZ K. ET AL., NATURE MEDICINE, vol. 13, 2007, pages 492 - 497
MOLINA-HOLGADO ET AL., EUR. J. NEUROSCI., vol. 25, 2007, pages 629 - 634
MUNRO ET AL., NATURE, vol. 365, 1993, pages 61 - 65
OFEK ET AL., PNAS, vol. 103, 2006, pages 696 - 701
PALAZUELOS J. ET AL., FASEB J., vol. 20, 2006, pages 2405 - 2407
PERTWEE ET AL.: "Handb. Exp. Pharmacol.", vol. 168, 2005, pages: 1 - 51
PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 90, 2008, pages 501 - 511
PIETR ET AL., FEBS LETT., vol. 583, 2009, pages 2071 - 2076
STELLA ET AL., GLIA, vol. 48, 2004, pages 267 - 277
WALTER ET AL., J. NEUROSCI., vol. 23, 2003, pages 1398 - 1405
YIANGOU ET AL., BMC. NEUROL., vol. 6, 2006, pages 12
ZHANG ET AL., EUR. J. NEUROSCI., vol. 17, 2003, pages 2750 - 2754

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013005168A3 (fr) * 2011-07-05 2013-04-25 Lupin Limited Modulateurs des récepteurs de cannabinoïdes
WO2017062500A3 (fr) * 2015-10-05 2017-05-26 The Trustees Of Columbia University In The City Of New York Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
WO2018067589A1 (fr) * 2015-10-05 2018-04-12 The Trustees Of Columbia University In The City Of New York Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
IL265750A (en) * 2015-10-05 2019-06-30 Univ Columbia Autophagic and phospholipase current activators and protein deposition including tau and proteinopathy
CN110023289A (zh) * 2015-10-05 2019-07-16 纽约市哥伦比亚大学理事会 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
US10487091B2 (en) 2015-10-05 2019-11-26 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US10865214B2 (en) 2015-10-05 2020-12-15 The Trustees of Columbia University in they City of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11008341B2 (en) 2015-10-05 2021-05-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11230558B2 (en) 2015-10-05 2022-01-25 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11261199B2 (en) 2015-10-05 2022-03-01 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN112384503A (zh) * 2018-07-02 2021-02-19 洛桑联邦理工学院(Epfl) 乳酸增强化合物及其用途

Also Published As

Publication number Publication date
WO2012090179A3 (fr) 2012-10-04

Similar Documents

Publication Publication Date Title
JP6218860B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
JP5700836B2 (ja) Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
CN108383836B (zh) 作为mek抑制剂的杂环基化合物
US7998982B2 (en) Amide derivatives as TRPV1 antagonists
CA2870992C (fr) Derives d'amide comme bloqueurs de ttx-s
CA2934702A1 (fr) Inhibiteurs de glutaminase
US20080269193A1 (en) Tetrahydroindole and Tetrahydroindazole Derivatives
BG97632A (bg) Индолови производни,методи и междинни съединенияза тяхното получаване,фармацевтични състави,коитоги съдържат,и тяхното приложение
RS57332B1 (sr) Heterociklični amidi kao inhibitori kinaze
WO1999003855A1 (fr) Derives de piperazine
JP2012502986A (ja) Ｐ２ｘ３受容体活性のモジュレーター
JP2022521536A (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
JP2008543726A (ja) 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
KR102711647B1 (ko) 신규한 tnf 활성 억제제 화합물 및 이의 약학적으로 허용가능한 염
CA2883172A1 (fr) Inhibiteurs de ddr2 pour le traitement de l'arthrose
JP2007522142A (ja) Ｉｋｋ３に対して活性を有するベンゾイミダゾール置換チオフェン誘導体
WO2016088838A1 (fr) Dérivé de purine et composition pharmaceutique le contenant
JP2023516235A (ja) Ｓｓｔｒ５アンタゴニスト
CA3198096A1 (fr) Derives d'aryle pour le traitement de troubles a mediation par trpm3
WO2017204316A1 (fr) Dérivé de 5-oxo-1,2,4-triazine et composition pharmaceutique correspondante
AU2005251920A1 (en) Chromone derivatives useful as vanilloid antagonists
WO2012090179A2 (fr) Dérivés d'isoquinoline en tant que modulateurs des récepteurs cannabinoïdes
WO2015052675A1 (fr) Utilisation de composés substitués dihydro-benzimidazole comme modulateurs du ror gamma
US9006442B2 (en) Cannabinoid receptor modulators
WO2012090177A2 (fr) Modulateurs des récepteurs cannabinoïdes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811575

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811575

Country of ref document: EP

Kind code of ref document: A2